{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T04:41:59Z","timestamp":1774327319879,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,4,12]],"date-time":"2014-04-12T00:00:00Z","timestamp":1397260800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s10792-014-9945-5","type":"journal-article","created":{"date-parts":[[2014,4,11]],"date-time":"2014-04-11T16:28:28Z","timestamp":1397233708000},"page":"303-310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Optic neuritis in Hong Kong: a 1-year follow-up study"],"prefix":"10.1007","volume":"35","author":[{"given":"Patrick P. K.","family":"Lau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon S. K.","family":"Yau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacky W. Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winnie W. Y.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor T. Y.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric Y. T.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris M. W.","family":"Tse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Can Y. F.","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,12]]},"reference":[{"issue":"6","key":"9945_CR1","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/ICU.0b013e328358b202","volume":"23","author":"N Nale","year":"2012","unstructured":"Nale N (2012) Management of optic neuritis as a clinically first event of multiple sclerosis. Curr Opin Ophthalmol 23(6):472\u2013476","journal-title":"Curr Opin Ophthalmol"},{"issue":"7","key":"9945_CR2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/eye.2011.81","volume":"25","author":"D Pau","year":"2011","unstructured":"Pau D, Al Zubidi N, Yalamanchili S, Plant GT, Lee AG (2011) Optic neuritis. Eye (LOND) 25(7):833\u2013842","journal-title":"Eye (LOND)"},{"key":"9945_CR3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s100720170011","volume":"22","author":"G Rosati","year":"2001","unstructured":"Rosati G (2001) The prevalence of multiple sclerosis in the world: an update. Neurol Sci 22:117\u2013139","journal-title":"Neurol Sci"},{"key":"9945_CR4","first-page":"82","volume":"16","author":"PH Shams","year":"2009","unstructured":"Shams PH, Plant GT (2009) Optic neuritis: a review. Int MS J 16:82\u201389","journal-title":"Int MS J"},{"key":"9945_CR5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","volume":"326","author":"RW Beck","year":"1992","unstructured":"Beck RW, Cleary PA, Anderson MM Jr et al (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 326:581\u2013588","journal-title":"N Engl J Med"},{"issue":"2","key":"9945_CR6","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O\u2019Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292\u2013302","journal-title":"Ann Neurol"},{"key":"9945_CR7","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485\u20131489","journal-title":"Neurology"},{"key":"9945_CR8","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6:805\u2013815","journal-title":"Lancet Neurol"},{"key":"9945_CR9","doi-asserted-by":"crossref","unstructured":"Clerico M, Faggiano F, Palace J, Rice G, Tintor\u00e8 M, Durelli L (2008) Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst Rev 16(2):CD005278. doi: 10.1002\/14651858.CD005278.pub3","DOI":"10.1002\/14651858.CD005278.pub3"},{"issue":"1\u20132","key":"9945_CR10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jns.2010.07.011","volume":"298","author":"S Jarius","year":"2010","unstructured":"Jarius S, Frederikson J, Waters P, Paul F, Akman-Demir G, Marignier R, Franciotta D, Ruprecht K, Kuenz B, Rommer P, Kristoferitsch W, Wildemann B, Vincent A (2010) Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 298(1\u20132):158\u2013162","journal-title":"J Neurol Sci"},{"issue":"1","key":"9945_CR11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0213-4853(10)70016-5","volume":"25","author":"Y Blanco","year":"2010","unstructured":"Blanco Y, Hankiewicz K, Llufriu S, Sabater L, Graus F, Saiz A, Grupo Espanol de Neuromielitis Optica (2010) Clinical spectrum associated with aquaporin-4 antibodies. Neurologia 25(1):5\u201312","journal-title":"Neurologia"},{"issue":"18","key":"9945_CR12","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1212\/WNL.0b013e3182190f74","volume":"76","author":"N Asgari","year":"2011","unstructured":"Asgari N, Lillevang ST, Skejoe HP, Falah M, Stenager E, Kyvik KO (2011) A population based study of neuromeylitis optica in Caucasians. Neurology 76(18):1589\u20131595. doi: 10.1212\/WNL.0b013e3182190f74","journal-title":"Neurology"},{"key":"9945_CR13","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1177\/1352458507084595","volume":"14","author":"Romain Marignier","year":"2008","unstructured":"Marignier Romain, De Seze Jerome, Vukusic Sandra, Durand-Dubief Francoise, Zephir Helene, Vermersch Patrick, Cabre Philippe, Cavillon Gaelle, Honorat Jerome, Confavreux Christian (2008) NMO-IgG and Devic\u2019s neuromyelitis optica: a French experience. Multiple Sclerosis 14:440\u2013445","journal-title":"Multiple Sclerosis"},{"issue":"1","key":"9945_CR14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/WNO.0b013e3181f8a693","volume":"31","author":"C Lai","year":"2011","unstructured":"Lai C, Tian G, Takahashi T, Liu W, Yang L, Zhang X (2011) Neuromyelitis optica antibodies in patients with severe optic neuritis in China. J Neuroophthalmol 31(1):16\u201319","journal-title":"J Neuroophthalmol"},{"issue":"11","key":"9945_CR15","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","volume":"131","author":"S Jarius","year":"2008","unstructured":"Jarius S, Aboul Enein F, Waters P, Kuenz B, Hauser A, Berger T, Lang W, Reindl M, Vincent A, Kristoferitsch W (2008) Antibody to aquaporin 4 in the long term course of neuromyelitis optica. Brain 131(11):3072\u20133080","journal-title":"Brain"},{"key":"9945_CR16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2377-10-45","volume":"10","author":"H Nakajima","year":"2010","unstructured":"Nakajima H, Hosokawa T, Sugino M, Kimura F, Sugasawa J, Hanafusa T, Takahashi T (2010) Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis. BMC Neurol 10:45","journal-title":"BMC Neurol"},{"issue":"8","key":"9945_CR17","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1468-1331.2007.01736.x","volume":"14","author":"K Kallenbach","year":"2007","unstructured":"Kallenbach K, Frederiksen J (2007) Optical coherence tomography in optic neuritis and multiple sclerosis: a review. Eur J Neurol 14(8):841\u2013849","journal-title":"Eur J Neurol"},{"issue":"4","key":"9945_CR18","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1212\/WNL.0b013e3181af78b8","volume":"73","author":"JN Ratchford","year":"2009","unstructured":"Ratchford JN, Quigg ME, Conger A et al (2009) Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology 73(4):302\u2013308","journal-title":"Neurology"},{"key":"9945_CR19","doi-asserted-by":"crossref","unstructured":"Yau GSK, Lee JWY, Lau PPK, Tam VTY, Wong WWY, Yuen CYF (2013) Prospective study on retinal nerve fibre layer thickness changes in isolated unilateral retrobulbar optic neuritis. Sci World J 2013, Article ID 694613, 4 pages, 2013. doi: 10.1155\/2013\/694613","DOI":"10.1155\/2013\/694613"},{"issue":"5","key":"9945_CR20","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1212\/WNL.49.5.1404","volume":"49","author":"Optic Neuritis Study Group","year":"1997","unstructured":"Optic Neuritis Study Group (1997) The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology 49(5):1404\u20131413","journal-title":"Neurology"},{"key":"9945_CR21","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1001\/archneur.61.9.1386","volume":"61","author":"Optic Neuritis Study Group","year":"2004","unstructured":"Optic Neuritis Study Group (2004) Long-term brain magnetic resonance imaging changes after optic neuritis in patients without clinically definite multiple sclerosis. Arch Neurol 61:1538\u20131541","journal-title":"Arch Neurol"},{"issue":"6","key":"9945_CR22","first-page":"727","volume":"65","author":"The Optic Neuritis Study Group","year":"2008","unstructured":"The Optic Neuritis Study Group (2008) Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 65(6):727\u2013732","journal-title":"Arch Neurol"},{"key":"9945_CR23","first-page":"885","volume":"51","author":"SR Cole","year":"1998","unstructured":"Cole SR, Beck RW, Moke PS et al (1998) The predictive value of CSF oligoclonal banding for MS 5\u00a0years after optic neuritis. Optic Study Group. Neurology. 51:885\u2013887","journal-title":"Optic Study Group. Neurology."},{"key":"9945_CR24","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fukihara K, Nakashima I, Weinshenker BG (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106\u20132112","journal-title":"Lancet"},{"issue":"9139","key":"9945_CR25","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","volume":"352","author":"PRISM (Prevention of Relapses and Disability by Interferon beta 1a Subcutaneously in Multiple Sclerosis) study group","year":"1998","unstructured":"PRISM (Prevention of Relapses and Disability by Interferon beta 1a Subcutaneously in Multiple Sclerosis) study group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. Lancet 352(9139):1498\u20131504","journal-title":"Lancet"},{"issue":"10","key":"9945_CR26","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1177\/1352458512439439","volume":"18","author":"SH Kim","year":"2012","unstructured":"Kim SH, Kim W, Li XF, Jung IJ, Kim HJ (2012) Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler 18(10):1480\u20131483","journal-title":"Mult Scler"},{"issue":"7","key":"9945_CR27","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","volume":"77","author":"C Costanzi","year":"2011","unstructured":"Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, Thapa P, McKeon A (2011) Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 77(7):659\u2013666","journal-title":"Neurology"},{"issue":"9","key":"9945_CR28","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","volume":"66","author":"A Jacob","year":"2009","unstructured":"Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, Carter J, Keegan BM, Kantarci OH, Pittock SJ (2009) Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 66(9):1128\u20131133","journal-title":"Arch Neurol"},{"issue":"11","key":"9945_CR29","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","volume":"65","author":"A Jacob","year":"2008","unstructured":"Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M, Constantinescu CS, Miller A, De Angelis T, Matiello M, Cree BA (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65(11):1443\u20131448","journal-title":"Arch Neurol"},{"key":"9945_CR30","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/WNO.0b013e3181f68c19","volume":"30","author":"SL Galetta","year":"2010","unstructured":"Galetta SL, Cornblath WT (2010) Should most patients with optic neuritis be tested for neuromyelitis optica antibodies and should this affect their treatment? J Neuro-ophthalmol 30:376\u2013379","journal-title":"J Neuro-ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-014-9945-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-014-9945-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-014-9945-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T20:30:34Z","timestamp":1559248234000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-014-9945-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,12]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["9945"],"URL":"https:\/\/doi.org\/10.1007\/s10792-014-9945-5","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,12]]}}}